Status:
COMPLETED
Metabolic Effects of a Thermogenic Ready-to-drink Beverage
Lead Sponsor:
Texas Tech University
Collaborating Sponsors:
EHP Labs
Conditions:
Metabolic Rate
Metabolism
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
This study is a randomized, double-blind, placebo-controlled crossover trial examining the metabolic effects of a novel ready-to-drink (RTD) beverage. Healthy adult males and females will be recruited...
Detailed Description
The primary purpose of this study is to report the metabolic effects of a new ready-to-drink (RTD) version of EHP Labs OxyShred Thermogenic Fat Burner. Additionally, the effect of this product on hemo...
Eligibility Criteria
Inclusion
- The inclusion criteria are:
- Between the ages of 18 and 40.
- Body mass between 50 - 110 kg (110 - 220 lbs.).
- Either: (A) Resistance-trained, defined as completing 3+ resistance training sessions per week for at least two years prior to screening; full body (all upper body and lower body major muscle groups) must be trained at least once weekly, OR (B) non-resistance trained, defined as never having followed a structured resistance training program.
- Perform ≤ 30 minutes of high-intensity interval training per week.
- Perform ≤ 60 minutes of steady state endurance exercise per week.
- Regular caffeine consumption (due to the presence of caffeine in the commercially available dietary supplement). This will be defined as an average self-reported daily intake of 200+ mg of caffeine, which is equivalent to approximately 2 cups of coffee.
- The exclusion criteria are:
- Failing to meet any of the aforementioned inclusion criteria.
- Presence of any known disease or medical condition which could be negatively affected by consumption of the beverage. This includes cardiovascular disease or condition; liver disease or disorder; other metabolic disease or disorder; or other conditions that could reasonably be deemed to contraindicate the study protocol.
- Pregnant or breastfeeding, based on self-report (for female participants).
- Taking medication which could reasonably make participation unsafe for the participant or influence study outcomes. Specifically, use of any prescription stimulant (e.g., dextroamphetamine (Dexedrine®), dextroamphetamine/amphetamine combination product (Adderall®), methylphenidate (Ritalin®, Concerta®), or similar stimulants) precludes participation in this study.
- Self-reported caffeine sensitivity, as indicated by unwanted side effects when caffeine is consumed.
- Allergy to any of the ingredients in the RTD beverage.
- Presence of a pacemaker or other implanted electrical device
- Self-reported claustrophobia (due to metabolism testing)
Exclusion
Key Trial Info
Start Date :
January 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 6 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT05194475
Start Date
January 18 2022
End Date
May 6 2022
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Kinesiology & Sport Management
Lubbock, Texas, United States, 79409